Theravance Biopharma
TBPH
98 hedge funds and large institutions have $794M invested in Theravance Biopharma in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 15 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 21
0.21% more ownership
Funds ownership: 86.4% → 86.61% (+0.21%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 104 → 98 (-6)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
28% less capital invested
Capital invested by funds: $1.1B → $794M (-$305M)
87% less call options, than puts
Call options by funds: $2.26M | Put options by funds: $17.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$9.35M |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
+$5.23M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$4.48M |
| 4 |
JG
Jefferies Group
New York
|
+$4.37M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$3.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
-$24.7M |
| 2 |
Morgan Stanley
New York
|
-$2.6M |
| 3 |
JP Morgan Chase
New York
|
-$2.18M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.88M |
| 5 |
OWIM
Old West Investment Management
Los Angeles,
California
|
-$1.76M |
TBPH Hedge Fund Activity: Q2 2019 in Review
98 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2019, worth a combined $794M — down 28% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TBPH and 11 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 38 added.
The largest buyer was Ameriprise, opening a new position worth an estimated $9.35M. The largest seller was Woodford Investment Management, cutting an estimated $24.7M.
- 98 institutional investors held Theravance Biopharma (TBPH) as of Q2 2019, down from 104 in Q1 2019.
- Funds reported $794M of Theravance Biopharma stock for Q2 2019, down 28% quarter-over-quarter.
- 11 funds opened new Theravance Biopharma positions in Q2 2019 and 15 closed out, a net change of -4 holders.
- The largest Theravance Biopharma buyer in Q2 2019 was Ameriprise, an estimated $9.35M added.
- The largest Theravance Biopharma seller in Q2 2019 was Woodford Investment Management, an estimated $24.7M sold.
Based on aggregated 13F filings for Q2 2019.